ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to exploit the unique capabilities of the revolutionary polyNaut® technology.

PolyNaut® is a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This innovative technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials creating ‘a bionic nanoparticle.’ The highly adaptable polymer structure of polyNaut® can be formulated to encapsulate a wide array of genetic cargoes, with sizes exceeding current standards for viral and non-viral delivery. Notably, it enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling.

PolyNaut® is set apart from conventional non-viral delivery technologies through its remarkable ability to target specific cells and penetrate biological barriers, including the challenging blood-brain barrier. PolyNaut® nanoparticles, when functionalised for CNS delivery through transcytosis, exhibit exceptional brain uptake.

Deploying its state-of-the-art polyNaut® platform, ViaNautis is at the forefront of pioneering new therapies for CNS diseases and cystic fibrosis. The company is actively building an internal pipeline and collaborating with leading pharmaceutical and biotech companies to unlock the potential of promising genetic molecules as well as new therapeutic platforms.

Biotechnology

Life Sciences

Pharmaceutical

Therapeutics

Vianautis

Stephanie Sutton

Sam Barker

Marius Kausas

Denis Cecchin

Giuseppe Battaglia

The Leadership Team at ViaNautis is responsible for steering the company towards its mission of leveraging the revolutionary polyNaut® technology for advanced therapeutic solutions. This team leads strategic decision-making, oversees business operations, fosters scientific and technological innovation, and ensures successful collaborations with pharmaceutical and biotech partners. Through their collective expertise, they guide the company in pioneering new therapies for CNS diseases and cystic fibrosis while building a robust internal pipeline and expanding the potential of polyNaut® technology.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Vianautis

Research and Development